Anti-EMAP II monoclonal antibody

About Allinaire Therapeutics

Allinaire Therapeutics is a preclinical-stage biotech focused on a novel, cytokine-targeted approach to treating severe cardiopulmonary diseases, with its lead program aimed at pulmonary arterial hypertension (PAH). The company's core asset is a humanized monoclonal antibody against EMAP II, a pathogenic cytokine implicated in vascular dysfunction, inflammation, and cell injury. Backed by experienced scientific founders and a management team with deep industry expertise, Allinaire is advancing its antibody through preclinical development with the goal of addressing a significant unmet medical need in PAH, where current therapies are largely symptomatic.

Therapeutic Areas

Other Pulmonary Arterial Hypertension (PAH) Drugs